These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
129 related articles for article (PubMed ID: 6360431)
41. Impulsivity, aggression, and neuroendocrine responses to serotonergic stimulation in substance abusers. Fishbein DH; Lozovsky D; Jaffe JH Biol Psychiatry; 1989 Apr; 25(8):1049-66. PubMed ID: 2720017 [TBL] [Abstract][Full Text] [Related]
42. The prolactin response to fenfluramine in depression: effects of melancholia and baseline cortisol. Mulder RT; Porter RJ; Joyce PR J Psychopharmacol; 2003 Mar; 17(1):97-102. PubMed ID: 12680745 [TBL] [Abstract][Full Text] [Related]
43. Seasonal variation in plasma prolactin response to D-fenfluramine in healthy subjects. Monteleone P; La Rocca A; Fuschino A; Bortolotti F; Maj M Psychoneuroendocrinology; 1999 Feb; 24(2):201-8. PubMed ID: 10101728 [TBL] [Abstract][Full Text] [Related]
44. Test-retest reliability of the prolactin and cortisol responses to D,L-fenfluramine challenge in disruptive behavior disorders. Stoff DM; Pasatiempo AP; Yeung JH; Bridger WH; Rabinovich H Psychiatry Res; 1992 Apr; 42(1):65-72. PubMed ID: 1603882 [TBL] [Abstract][Full Text] [Related]
45. Serotonin and norepinephrine-dependent effects of fenfluramine on plasma renin activity in conscious male rats. Van de Kar LD; Richardson KD; Urban JH Neuropharmacology; 1985 Jun; 24(6):487-94. PubMed ID: 3160963 [TBL] [Abstract][Full Text] [Related]
46. Effects of metoclopramide and bromocriptine on the renin-angiotensin-aldosterone system in man. Dopaminergic control of aldosterone. Carey RM; Thorner MO; Ortt EM J Clin Invest; 1979 Apr; 63(4):727-35. PubMed ID: 438333 [TBL] [Abstract][Full Text] [Related]
47. Hormonal responses to d- and d,l-fenfluramine in healthy human subjects. Coccaro EF; Kavoussi RJ; Cooper TB; Hauger RL Neuropsychopharmacology; 1996 Dec; 15(6):595-607. PubMed ID: 8946434 [TBL] [Abstract][Full Text] [Related]
48. Effect of fenfluramine on insulin/growth hormone ratio in obese subjects. Altomonte L; Zoli A; Ghirlanda G; Manna R; Greco AV Pharmacology; 1988; 36(2):106-11. PubMed ID: 3281173 [TBL] [Abstract][Full Text] [Related]
49. Prolactin and cortisol responses to fenfluramine challenge in mania. Yatham LN Biol Psychiatry; 1996 Feb; 39(4):285-8. PubMed ID: 8645775 [TBL] [Abstract][Full Text] [Related]
50. Effect of fenfluramine oral administration on serum prolactin levels in healthy and hyperprolactinemic women. Scarduelli C; Mattei AM; Brambilla G; Zavaglia C; Adelasco P; Cavioni V; Ferrari C Gynecol Obstet Invest; 1985; 19(2):92-6. PubMed ID: 3988149 [TBL] [Abstract][Full Text] [Related]
51. Timing of neuroendocrine responses and effect of m-CPP and fenfluramine plasma levels in OCD. Hollander E; Cohen LJ; DeCaria C; Saoud JB; Stein DJ; Cooper TB; Islam NN; Liebowitz MR; Klein DF Biol Psychiatry; 1993 Sep; 34(6):407-13. PubMed ID: 8218609 [TBL] [Abstract][Full Text] [Related]
52. Impulsiveness and the prolactin response to d-fenfluramine. Evans J; Platts H; Lightman S; Nutt D Psychopharmacology (Berl); 2000 Apr; 149(2):147-52. PubMed ID: 10805609 [TBL] [Abstract][Full Text] [Related]
53. Effect of metergoline on the aldosterone-stimulating properties of metoclopramide. Opocher G; Murgia A; Boscaro M; D'Agostino D; Fallo F; Mantero F J Steroid Biochem; 1983 Jul; 19(1B):531-6. PubMed ID: 6350721 [TBL] [Abstract][Full Text] [Related]
54. Reduced prolactin and cortisol responses to d-fenfluramine in depressed compared to healthy matched control subjects. Cleare AJ; Murray RM; O'Keane V Neuropsychopharmacology; 1996 May; 14(5):349-54. PubMed ID: 8703303 [TBL] [Abstract][Full Text] [Related]
55. Effect of midbrain raphe lesion or 5,7-dihydroxytryptamine treatment on the prolactin-releasing action of quipazine and D-fenfluramine in rats. Quattrone A; Schettini G; di Renzo G; Tedeschi G; Preziosi P Brain Res; 1979 Sep; 174(1):71-9. PubMed ID: 487124 [TBL] [Abstract][Full Text] [Related]
56. Temporal changes in prolactin and corticosterone response during chronic treatment with d-fenfluramine. Serri O; Rasio E Horm Res; 1989; 31(4):180-3. PubMed ID: 2793072 [TBL] [Abstract][Full Text] [Related]
57. Effect of domperidone, an extracerebral inhibitor of dopamine receptors, on thyrotropin, prolactin, renin, aldosterone, and 18-hydroxycorticosterone secretion in man. Sowers JR; Sharp B; McCallum RW J Clin Endocrinol Metab; 1982 Apr; 54(4):869-71. PubMed ID: 7037817 [TBL] [Abstract][Full Text] [Related]